Letter: hepatocellular carcinoma risk in patients with non-selective beta blockers

Aliment Pharmacol Ther. 2021 Oct;54(8):1093-1094. doi: 10.1111/apt.16576.

Authors

Daniel Q Huang^{1

2}, Mindie H Nguyen^{3

4}

Affiliations

¹ Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
² Division of Gastroenterology and Hepatology, National University Health System, Singapore.
³ Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, California, USA.
⁴ Department of Epidemiology and Population Health, Stanford University Medical Center, Palo Alto, California, USA.

PMID: 34564887
DOI: 10.1111/apt.16576

No abstract available

Publication types

Letter
Comment

MeSH terms

Adrenergic beta-Antagonists / adverse effects
Carcinoma, Hepatocellular* / epidemiology
Humans
Liver Cirrhosis
Liver Neoplasms* / epidemiology

Substances

Adrenergic beta-Antagonists